Skip to main content
TipRanks
Go Ultimate75% OFF

PharmGen Science, Inc. (004720) Stock Statistics & Valuation Metrics

Total Valuation

PharmGen Science, Inc. has a market cap or net worth of KRW 68.40B. The enterprise value is KRW 45.24B.

Market Cap
KRW 68.40B
Enterprise Value
KRW 45.24B

Share Statistics

PharmGen Science, Inc. has 22,654,366 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
22,654,366
Owned by Insiders
―
Owned by Institutions
0.27%

Financial Efficiency

PharmGen Science, Inc.’s return on equity (ROE) is -0.80 and return on invested capital (ROIC) is 2.76%.

Return on Equity (ROE)
-0.80
Return on Assets (ROA)
-0.60
Return on Invested Capital (ROIC)
2.76%
Return on Capital Employed (ROCE)
0.04
Revenue Per Employee
755.78M
Profits Per Employee
-509.35M
Employee Count
229
Asset Turnover
0.89
Inventory Turnover
2.25

Valuation Ratios

The current PE Ratio of PharmGen Science, Inc. is -0.49. PharmGen Science, Inc.’s PEG ratio is 0.00.

PE Ratio
-0.49
PS Ratio
0.39
PB Ratio
0.47
Price to FCF
4.55
Price to Operating Cash Flow
3.84
PEG Ratio
0.00

Income Statement

In the last 12 months, PharmGen Science, Inc. had revenue of 173.07B and earned -116.64B in profits. Earnings per share was -5312.85.

Revenue
173.07B
Gross Profit
109.13B
Operating Income
5.99B
Pretax Income
-151.10B
Net Income
-116.64B
EBITDA
10.53B
Earnings Per Share (EPS)
-5312.85

Cash Flow

In the last 12 months, operating cash flow was 17.33B and capital expenditures -2.39B, giving a free cash flow of 14.94B billion.

Operating Cash Flow
17.33B
Free Cash Flow
14.94B
Free Cash Flow per Share
675.35

Dividends & Yields

PharmGen Science, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
21.84%
Earnings Yield
-200.78%

Stock Price Statistics

Beta
-0.07
52-Week Price Change
-26.93%
50-Day Moving Average
2872.50
200-Day Moving Average
3367.55
Relative Strength Index (RSI)
64.73
Average Volume (3m)
18.61K

Important Dates

PharmGen Science, Inc. upcoming earnings date is Nov 18, 2026, TBA (Not Confirmed).

Last Earnings Date
Aug 14, 2026
Next Earnings Date
Nov 18, 2026
Ex-Dividend Date
―

Financial Position

PharmGen Science, Inc. as a current ratio of 2.85, with Debt / Equity ratio of 4.10%

Current Ratio
2.85
Quick Ratio
2.01
Debt to Market Cap
0.06
Net Debt to EBITDA
-1.51
Interest Coverage Ratio
4.30

Taxes

In the past 12 months, PharmGen Science, Inc. has paid -34.46B in taxes.

Income Tax
-34.46B
Effective Tax Rate
0.23

Enterprise Valuation

PharmGen Science, Inc. EV to EBITDA ratio is 5.77, with an EV/FCF ratio of 3.32.

EV to Sales
0.28
EV to EBITDA
5.77
EV to Free Cash Flow
3.32
EV to Operating Cash Flow
2.86

Balance Sheet

PharmGen Science, Inc. has KRW 20.05B in cash and marketable securities with KRW 698.13M in debt, giving a net cash position of KRW 19.35B billion.

Cash & Marketable Securities
KRW 20.05B
Total Debt
KRW 698.13M
Net Cash
KRW 19.35B
Net Cash Per Share
KRW 854.31
Tangible Book Value Per Share
KRW 6,006.99

Margins

Gross margin is 64.26%, with operating margin of 2.22%, and net profit margin of -76.62%.

Gross Margin
64.26%
Operating Margin
2.22%
Pretax Margin
-96.69%
Net Profit Margin
-76.62%
EBITDA Margin
4.90%
EBIT Margin
2.22%

Analyst Forecast

The average price target for PharmGen Science, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target
―
Price Target Upside
―
Analyst Consensus
―
Analyst Count
―
Revenue Growth Forecast
0.42%
EPS Growth Forecast
-4001.63%

Scores

Smart Score
―
AI Score
50